Although our findings suggest that MM may have a good prognosis, it remains uncertain whether this is related to the delay of onset of disease, the time when cancer develops or the time when patients reach their death.
Multiple myeloma is a incurable condition due to constant relapses. However, new chemotherapy regimens for relapsed myeloma carry a cure rate up to 75% in patients who are refractory to first-line therapy. This cure rate seems to be higher if the disease is localized or has a low burden of bone lesions. The effect of chemotherapy on progression-free survival varies with initial disease burden and age.
These signs may include a mass in the kidneys or spine, a low blood cell count, or protein in the urine. It can, however, take time to be diagnosed. The signs of multiple myeloma may also change over time. Patients should contact their doctor when they are in these signs of multiple myeloma. They may also experience pain that comes and goes.
The prevalence of MM is 2.6% a year in US population, which accounts for about 1.6% of all deaths and 4.5% of all years of disability expenditures of US in 2007. In the United States, MM is diagnosed mainly in elderly populations. The most common presenting clinical manifestations of MM are proteus-form plasmablastic lesions, extramedullary plasmablastic lesions, and myelofibrosis.
The current study identified a low level of satisfaction among patients with MM receiving hospice care. Results from a recent clinical trial underscore the importance of improving satisfaction with end of life care for patients with MM.
Almost all MMs receive treatment with bortezomib and dexamethasone. The addition of thalidomide represents a change, but, when used in combination with bortezomib and dexamethasone, it appears to confer incremental benefit in terms of PFS and OS.
Myeloma can occur by different mechanisms (such as genetic susceptibility, cancer triggers, or exposures to radiotherapy) and seems to be associated with [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) in different families. It also appears as a complication of another tumor and/or a therapy-related condition when it occurs in patients who had undergone more than one treatment.
This review confirms the most commonly observed combination of carfilzomib in combination with bortezomib. Although combinations of carfilzomib plus sorafenib, lenalidomide, and dexamethasone are found, there is substantial clinical uncertainty regarding this combination due the risk of high-dose dexamethasone related to cardiotoxicity and the limited number of patients (only 4 of 29 patients) in the phase I clinical trial.
Patients with multiple myeloma have been able to expect an improvement in their outcomes with new therapies, especially when they are responding as well as when they are responding to an initial therapy. Although some drugs have been discovered, their use as single agents is limited especially when patients are progressing. Nevertheless, they can be combined to try to improve the clinical outcome.
Treatment with carfilzomib results in robust responses in [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) patients expressing both autocrine VEGF and hypoxic stress in the microenvironment. The clinical benefit of carfilzomib in multiple myeloma patients highlights its potential for application in autotargeting of hypoxia-sensitive myeloma cells.
The primary cause of multiple myeloma was not definitively established. The disease is most likely to arise following excess exposure to the genetic predisposing agent(s) of multiple myeloma.
Currently there is no cure for this disease and the only way to prolong life is to control the disease; so patients need to use complementary treatments that will not only help to keep the patients on living longer but also help to slow down the progression of a disease that will probably end up as the number one cause of cancer deaths in the world.